Which medicine and use?
FDA approval concerns a finished product, its labeling and the supporting evidence. Printing the name of an ingredient used in an approved medicine on a different vial does not make that vial an approved medicine.
THE REGENLUMA PEPTIDE LEARNING CENTER
Understand peptides.
Explore the evidence.
Peptide medicines are changing care for specific health conditions. Learn what they do, where human research supports a benefit, and which questions still need answers.
Evidence and U.S. status checked October 21, 2026. Educational topics; availability and clinical suitability require confirmation.
THE FOUNDATIONS
Signals in the body.
Medicines with a purpose.
Peptides are chains of amino acids, the building blocks used to make proteins. Some act as signals in the body. A peptide medicine can interact with a receptor or biological pathway; the effect depends on the particular molecule, formulation and route.
“Peptide therapy” is a broad description. It includes established prescription medicines and experimental compounds. It is different from PRP, stem-cell therapy and acoustic-wave treatment, and it does not automatically mean tissue regeneration.
A convincing explanation connects the exact product to a diagnosis and a meaningful outcome: less disease burden, better function or a lower risk of a specific health event. A change in a hormone level, a laboratory experiment or a testimonial answers a different question. In this directory, GH means growth hormone and IGF-1 means insulin-like growth factor 1, a hormone involved in GH activity.
Sources: [50] FDA-approved labeling / DailyMed, [51] FDA-approved labeling / DailyMed, [53] FDA-approved labeling / DailyMed, [62] Teichman et al. / Journal of Clinical Endocrinology & Metabolism
KNOW WHICH QUESTION YOU ARE ASKING
Approval. Access. Evidence.
Three different things.
These distinctions help you understand a proposal before comparing benefits, risks and cost.
Why a custom preparation?
Compounding can address an individual medical need an approved medicine cannot meet. The preparation is not FDA approved. Applicable federal and state requirements still matter.
What has been shown in people?
Research can be promising before benefits and long-term risks are known. A study's size, comparison group, outcomes, route and follow-up determine what it can tell you.
Sources: [44] FDA, [45] FDA, [91] FDA
CURRENT FEDERAL UPDATE / OCTOBER 21, 2026
A policy under review is not an issued approval.
The White House Office of Information and Regulatory Affairs (OIRA) lists an FDA peptide compounding access policy received October 14, 2026 as pending review. FDA's July advisory meeting considered several peptides; advisory recommendations are non-binding. Neither step establishes that a peptide has been approved as safe and effective for a proposed use.
Sources: [47] FDA, [72] Office of Management and Budget / OIRA
Understand the current status ↗A PRACTICAL PEPTIDE DIRECTORY
Explore the names.
Understand the differences.
Browse 27 medicines and compounds patients commonly ask about. Categories describe areas of discussion or research; they do not establish a benefit or a RegenLuma service offering.
Showing all 27 entries.
Approved products · specific usesWeight & metabolism
Semaglutide
Wegovy; Ozempic and Rybelsus have their own labels
A GLP-1 receptor agonist used in specific prescription products for metabolic disease.
Read the evidence, limits & risks
What the evidence supports
Wegovy has weight-management and cardiovascular indications for eligible patients. Its injection also has a defined accelerated-approval indication for noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), an inflammatory fatty-liver disease, with moderate-to-advanced scarring (F2-F3 fibrosis). Formulation and patient eligibility matter.
What it does not establish
This does not establish an anti-aging or tissue-regeneration benefit. Ozempic, Rybelsus and Wegovy are not interchangeable indications or instructions.
What to discuss
Discuss gastrointestinal effects, pancreatitis, gallbladder disease, dehydration and kidney injury, pregnancy planning, and the boxed thyroid-tumor warning. A personal or family history of medullary thyroid carcinoma, or a diagnosis of multiple endocrine neoplasia type 2, is a contraindication.
Sources: [50] FDA-approved labeling / DailyMed, [82] National Library of Medicine / MedlinePlus
Approved products · specific usesWeight & metabolism
Tirzepatide
Zepbound; Mounjaro has its own label
A dual GIP/GLP-1 receptor agonist with substantial randomized human evidence.
Read the evidence, limits & risks
What the evidence supports
Zepbound is approved for eligible adults' weight management and for moderate-to-severe obstructive sleep apnea in adults with obesity, alongside diet and activity. Mounjaro is a different labeled product.
What it does not establish
Weight loss or improved sleep-apnea outcomes do not establish cartilage regrowth, athletic enhancement or general longevity.
What to discuss
Gastrointestinal symptoms and important pancreatic, gallbladder and dehydration risks require review. The boxed thyroid-tumor warning and contraindication for medullary thyroid carcinoma or multiple endocrine neoplasia type 2 apply. Ask about interactions with oral contraception.
Sources: [51] FDA-approved labeling / DailyMed, [83] National Library of Medicine / MedlinePlus
Approved products · specific usesWeight & metabolism
Liraglutide
Saxenda; Victoza has a different label
A GLP-1 medicine with established metabolic uses.
Read the evidence, limits & risks
What the evidence supports
Saxenda is an approved weight-management option for eligible patients. A clinician compares its evidence, practicality, risks and cost with other approaches.
What it does not establish
It is not a treatment for every person wanting to lose a few pounds, and approval does not establish a general regenerative effect.
What to discuss
Review the current Saxenda label, gastrointestinal adverse effects, thyroid-tumor contraindications and other product-specific precautions.
Sources: [52] FDA-approved labeling, [74] NIH / NIDDK
Approved product · narrow indicationGrowth hormone signaling
Tesamorelin
Egrifta WR
A growth hormone-releasing factor analog with a specific medical role.
Read the evidence, limits & risks
What the evidence supports
Egrifta WR reduces excess abdominal fat in adults with HIV-associated lipodystrophy.
What it does not establish
It is not indicated for general weight-loss management. Long-term cardiovascular safety is unestablished. Its approval does not apply to tesamorelin/ipamorelin mixtures.
What to discuss
Discuss cancer history, pituitary conditions, pregnancy, raised IGF-1, glucose intolerance and fluid retention. Monitoring follows the actual product label.
Historical approval · current compounds differGrowth hormone signaling
Sermorelin
Historical brand: Geref
Signals the pituitary to release growth hormone; commonly discussed in wellness clinics.
Read the evidence, limits & risks
What the evidence supports
Geref previously had childhood growth-hormone deficiency and diagnostic indications. FDA determined its discontinued products were not withdrawn for safety or effectiveness reasons.
What it does not establish
That history does not make today's compounded adult wellness products FDA approved or establish anti-aging benefits. A hormone response alone is not a patient-important outcome.
What to discuss
Ask why GH-directed treatment is appropriate, what clinical outcome is expected, and how glucose, IGF-1, adverse effects and product quality will be reviewed.
Sources: [61] FDA / Federal Register, [44] FDA, [49] National Library of Medicine / MedlinePlus
Unapproved · limited clinical outcomesGrowth hormone signaling
CJC-1295
Drug affinity complex (DAC) and no-DAC names require exact identification
A growth hormone-releasing hormone analog studied for hormonal effects.
Read the evidence, limits & risks
What the evidence supports
Short randomized studies in healthy adults showed increases in GH and IGF-1.
What it does not establish
Those studies did not establish better injury recovery, strength, daily function or longevity. Do not assume every product called CJC-1295 matches the studied molecule.
What to discuss
Long-term safety and meaningful benefit need better evidence; FDA identifies safety concerns. Combining it with another peptide does not establish the combination's effectiveness.
Sources: [62] Teichman et al. / Journal of Clinical Endocrinology & Metabolism, [86] FDA
Unapproved · route-specific evidenceGrowth hormone signaling
Ipamorelin
Often marketed in CJC-1295 or tesamorelin blends
A growth hormone secretagogue investigated in human clinical research.
Read the evidence, limits & risks
What the evidence supports
One randomized study used intravenous ipamorelin after bowel surgery.
What it does not establish
That setting does not validate subcutaneous anti-aging, muscle-building or injury-recovery programs. Results from one route do not prove safety of another.
What to discuss
Ask about the exact molecule, route and evidence; safety information for common wellness regimens is incomplete.
Sources: [63] Beck et al. / International Journal of Colorectal Disease, [87] FDA
Unapproved · very limited human evidenceRecovery & nerve research
BPC-157
Body protection compound; sometimes sold in recovery stacks
Investigated for tissue and gastrointestinal effects; widely marketed for recovery.
Read the evidence, limits & risks
What the evidence supports
A knee-pain report followed 17 patients retrospectively, reaching 16 by phone. A separate IV safety pilot enrolled two previously exposed adults.
What it does not establish
Neither provides controlled proof of tendon healing, cartilage regrowth or long-term safety. FDA’s 2026 briefing evaluated BPC-157 for ulcerative colitis and described major evidence and safety gaps.
What to discuss
Injection, product-quality and long-term biological risks need careful assessment. Testimonials cannot establish cause and effect.
Sources: [76] Lee & Padgett / Alternative Therapies in Health and Medicine, [77] Lee et al. / Alternative Therapies in Health and Medicine, [64] FDA
Unapproved · clinical evidence gapRecovery & nerve research
TB-500
Thymosin beta-4 fragment; identity must be confirmed
Marketed for healing, but frequently confused with full-length thymosin beta-4.
Read the evidence, limits & risks
What the evidence supports
Full-length topical thymosin beta-4 has been studied in venous ulcers. FDA's 2026 TB-500 review did not identify clinical studies establishing its human wound-healing benefit.
What it does not establish
An ulcer study of a different molecule applied to the skin does not validate injected TB-500 or a BPC-157/TB-500 stack.
What to discuss
The exact fragment, impurities, formulation and route matter. Appropriate human safety data remain inadequate.
Sources: [65] FDA, [84] Guarnera et al. / Annals of the New York Academy of Sciences
Route matters · injectable evidence limitedSkin & hair
GHK-Cu
Copper peptide; topical and injectable products differ
A copper-binding peptide investigated in skin biology and topical care.
Read the evidence, limits & risks
What the evidence supports
Small topical studies exist. One post-laser study had 13 completers and mixed findings: some patient-reported improvement without significant differences on blinded assessments.
What it does not establish
Topical results do not prove systemic injected benefits, hair restoration or longer life. Cosmetic availability is not FDA drug approval.
What to discuss
Injected GHK-Cu has limited human safety information. A topical product should never be assumed suitable for injection.
Sources: [78] Miller et al. / Archives of Facial Plastic Surgery, [89] FDA, [46] FDA
Not FDA approved · disease-specific researchImmune & inflammation
Thymosin alpha-1
Thymalfasin; distinct from thymosin beta-4
An immune-modulating peptide with human studies in particular illnesses.
Read the evidence, limits & risks
What the evidence supports
The 2025 TESTS sepsis trial enrolled 1,106 adults. Mortality at 28 days was 23.4% with thymosin alpha-1 versus 24.1% with placebo, without a clear mortality benefit.
What it does not establish
Sepsis research does not prove that healthy adults benefit from an immune-boosting program. Foreign approval or availability does not establish U.S. approval.
What to discuss
Benefits and safety depend on the disease, product and patient. Avoid substituting wellness claims for a diagnosis and established care.
Sources: [79] Wu et al. / BMJ, [88] FDA
Unapproved · weight-loss evidence disappointingWeight & metabolism
AOD-9604
Modified growth-hormone fragment
Promoted for fat loss, with a history of human obesity research.
Read the evidence, limits & risks
What the evidence supports
FDA's review describes a 536-patient study that did not show significant weight-loss benefit at its primary 12-week endpoint.
What it does not establish
Development for obesity was stopped. Evidence does not establish the benefits of commonly promoted subcutaneous fat-loss regimens.
What to discuss
A claim that a product avoids all growth-hormone risks does not establish its own safety or effectiveness.
Sources: [80] FDA
Unapproved · preclinical promiseMitochondria & longevity
MOTS-c
Mitochondrial-derived peptide
Studied in metabolism and exercise biology.
Read the evidence, limits & risks
What the evidence supports
FDA's July 2026 assessment did not identify clinical studies or human exposure data evaluating administered MOTS-c.
What it does not establish
Measuring a peptide naturally present in people is different from proving an injected medicine works. Animal findings do not establish human fat loss, performance or lifespan benefits.
What to discuss
Human dosing, clinical benefit and long-term safety are not established by the reviewed evidence.
Sources: [66] FDA
Unapproved · longevity claims unprovenMitochondria & longevity
Epitalon
Epithalon; different from pineal extracts
Marketed around telomeres, sleep and healthy aging.
Read the evidence, limits & risks
What the evidence supports
FDA's 2026 review found inadequate clinical evidence for insomnia and important gaps in human safety information.
What it does not establish
A cellular telomerase finding does not demonstrate a longer or healthier human life. Studies of other pineal preparations cannot automatically be attributed to epitalon.
What to discuss
Biological plausibility leaves unanswered questions about real-world benefit and long-term harm.
Sources: [67] FDA
Investigational · phase 3 evidenceWeight & metabolism
Retatrutide
Investigational triple GIP/GLP-1/glucagon receptor agonist
An important example of promising clinical research that is still investigational.
Read the evidence, limits & risks
What the evidence supports
TRIUMPH-1, published September 2026, randomized 2,339 adults. At 80 weeks, mean weight change in its highest studied group was -25.0%, versus -3.9% with placebo.
What it does not establish
It remained unapproved at this review. FDA states it cannot currently be used in compounding under federal law. Trial results are not prescribing instructions or evidence of cartilage regeneration.
What to discuss
Gastrointestinal events were common in the trial. Appropriate access is through legitimate research arrangements, not research-use-only products sold for self-treatment.
Sources: [73] Jastreboff et al. / New England Journal of Medicine, [48] FDA
Unapproved · preclinical evidenceImmune & inflammation
KPV
Lysine-proline-valine tripeptide
Investigated for inflammatory pathways and wound healing.
Read the evidence, limits & risks
What the evidence supports
FDA's 2026 review did not identify human clinical studies evaluating the nominated products.
What it does not establish
Laboratory, animal and cadaver-skin findings do not establish benefits for inflammatory bowel disease, general gut health or wound healing in patients.
What to discuss
The absence of reported side effects in an understudied product is not evidence of safety.
Sources: [70] FDA
Not FDA approved · uncertain clinical benefitSleep, mood & cognition
Semax
Marketed for cognition and neurological symptoms
Investigated for neurological conditions, with limited clinical information.
Read the evidence, limits & risks
What the evidence supports
FDA's 2026 assessment found insufficient evidence for the evaluated uses, including cerebral ischemia, migraine and trigeminal neuralgia.
What it does not establish
These data do not establish cognitive enhancement for healthy adults. Intranasal findings do not validate injected formulations.
What to discuss
Do not delay proven assessment or treatment for neurological symptoms in favor of a wellness peptide.
Sources: [69] FDA
Unapproved · limited clinical evidenceSleep, mood & cognition
DSIP / emideltide
Delta sleep-inducing peptide
Studied for sleep and other neurological uses.
Read the evidence, limits & risks
What the evidence supports
FDA's July 2026 review found inadequate effectiveness and safety information for the evaluated conditions.
What it does not establish
Its name is not proof that it reliably treats insomnia. Evidence for a specific molecule and route must be examined separately.
What to discuss
Persistent insomnia deserves a diagnosis and discussion of established treatments, including behavioral approaches.
Sources: [68] FDA
Approved product · defined diagnosisSexual health
Bremelanotide / PT-141
Approved finished product: Vyleesi
A melanocortin receptor agonist used for a specific sexual-health diagnosis.
Read the evidence, limits & risks
What the evidence supports
Vyleesi treats acquired, generalized hypoactive sexual desire disorder in premenopausal women when the label’s diagnostic exclusions have been assessed.
What it does not establish
It is not approved to enhance sexual performance or to treat men or postmenopausal HSDD. A vial sold as PT-141 is not automatically the approved Vyleesi product.
What to discuss
Contraindicated with uncontrolled hypertension or known cardiovascular disease. Discuss nausea, blood-pressure changes and other label precautions.
Sources: [54] FDA-approved labeling, [91] FDA
Approved products · osteoporosis careBone health
Teriparatide
Forteo and separately approved products
A parathyroid hormone analog used in selected patients at high fracture risk.
Read the evidence, limits & risks
What the evidence supports
Forteo has specific osteoporosis indications for postmenopausal women, men, and certain patients receiving long-term glucocorticoids.
What it does not establish
An osteoporosis approval is not proof of general injury recovery, tendon repair or cartilage regeneration.
What to discuss
Treatment selection considers calcium-related risks, kidney and bone history, orthostatic symptoms, hypersensitivity and duration of therapy.
Sources: [56] FDA-approved labeling
Approved product · osteoporosis careBone health
Abaloparatide
Tymlos
A parathyroid hormone-related peptide analog used for selected osteoporosis care.
Read the evidence, limits & risks
What the evidence supports
Tymlos has defined indications for postmenopausal women and men with osteoporosis at high fracture risk.
What it does not establish
This does not make it a general-purpose bone or soft-tissue regeneration product. A full osteoporosis plan is needed.
What to discuss
Discuss hypersensitivity, calcium-related risks, dizziness, kidney-stone history and the plan for treatment duration and follow-up.
Sources: [57] FDA-approved labeling
Accelerated approval · rare-disease indicationMitochondria & longevity
Elamipretide / SS-31
Approved finished product: Forzinity
A mitochondrial cardiolipin binder with an approved, narrowly defined medical role.
Read the evidence, limits & risks
What the evidence supports
Forzinity received accelerated approval in 2025 to improve muscle strength in adults and children with Barth syndrome weighing at least 30 kg. Confirmatory clinical benefit testing is required.
What it does not establish
This is not approval of general energy, anti-aging or mitochondrial-wellness claims, nor of every product sold as SS-31.
What to discuss
Review the actual product label, kidney-related considerations, injection-site reactions and hypersensitivity precautions with the treating specialist.
Sources: [55] FDA, [85] FDA-approved labeling, [91] FDA
Investigational · early human researchRecovery & nerve research
Cibinetide / ARA-290
Investigational innate repair receptor agonist
Studied for particular nerve-related disease outcomes.
Read the evidence, limits & risks
What the evidence supports
A 28-day randomized phase 2b study in 64 people with sarcoidosis-associated small nerve fiber loss examined nerve-fiber and symptom measures.
What it does not establish
Changes in nerve-fiber measurements in a small disease-specific study do not prove general pain relief, athletic recovery or a broadly effective nerve-regeneration service.
What to discuss
Meaningful clinical benefit, treatment durability and longer-term safety need further research.
Sources: [81] Culver et al. / Investigative Ophthalmology & Visual Science
Not FDA approved · limited evidenceSleep, mood & cognition
Selank
Selank acetate / TP-7; marketed for anxiety or cognition
A peptide promoted for brain and mood-related goals.
Read the evidence, limits & risks
What the evidence supports
The reviewed federal resources do not establish an approved U.S. anxiety or cognitive-enhancement medicine.
What it does not establish
Use or approval in another country does not establish U.S. approval, and an online listing does not establish clinical benefit.
What to discuss
Human safety information for marketed formulations and routes is inadequate; symptoms deserve appropriate clinical evaluation.
Not FDA approved · experimental usesImmune & inflammation
LL-37
Cathelicidin antimicrobial peptide
Studied in host-defense biology and disease-specific research.
Read the evidence, limits & risks
What the evidence supports
A natural role in immune biology is a reason for research, not proof that an injected treatment improves immunity.
What it does not establish
The reviewed evidence does not establish routine treatment of infection or an immune-boosting service.
What to discuss
FDA identifies inadequate safety information and nonclinical concerns. A biological mechanism does not establish a favorable benefit-risk balance.
Not FDA approved · safety concernsSkin & hair
Melanotan II
Different from other melanocortin medicines
Marketed online for tanning and sexual effects.
Read the evidence, limits & risks
What the evidence supports
It is not the approved Vyleesi product, and evidence for other melanocortin medicines cannot be transferred to it.
What it does not establish
A tanning response does not establish safety or protection from ultraviolet damage.
What to discuss
FDA identifies serious safety concerns. Discuss skin changes with a clinician; do not substitute tanning products for sun protection.
Investigational · not FDA approvedWeight & metabolism
Cagrilintide
Investigational long-acting amylin analog
Investigated for weight management, including combination approaches.
Read the evidence, limits & risks
What the evidence supports
It is a separate investigational molecule, not another name for semaglutide or tirzepatide.
What it does not establish
As of this review, FDA states cagrilintide is not an approved-drug component and cannot currently be used in compounding under federal law.
What to discuss
Trial participation and pharmacy access are different pathways. A product sold as a research chemical is not a clinical substitute.
Sources: [48] FDA
No matching entries. Try another name or reset the filters.
“Approved” identifies an approved finished product with specific uses, not every product bearing the molecule's name. “Unapproved” does not mean no research exists. This selected directory is not a catalogue of all peptide drugs.
GO DEEPER
A stronger decision
starts with the details.
Follow the topic that best matches the questions you want to bring to a clinician.
What can GLP-1 and GIP medicines offer?
Read major human trial results in context, understand eligible uses, and explore what long-term care and side-effect planning involve.
Explore weight-management medicines ↗What belongs in an evaluation?
Learn why product identity, medical history, appropriate blood work, pharmacy quality and follow-up matter.
Prepare for a safer conversation ↗QUESTIONS PATIENTS ASK
Clear answers.
Useful distinctions.
Are peptides natural, and does that make them safe?
A substance can occur naturally and still cause harm when given as a medicine. A manufactured analog, a different dose or a different route can change its effects. Safety is assessed for the actual product and patient, not inferred from the word “natural.”
Sources: [44] FDA, [50] FDA-approved labeling / DailyMed, [53] FDA-approved labeling / DailyMed
Do peptides repair joints or regrow cartilage?
No class-wide conclusion is justified. Small reports involving BPC-157 cannot establish cartilage regrowth. Medicines approved for osteoporosis address specific bone-health indications and do not validate every recovery peptide or soft-tissue claim.
Sources: [56] FDA-approved labeling, [57] FDA-approved labeling, [76] Lee & Padgett / Alternative Therapies in Health and Medicine
Are peptide stacks better than a single product?
A blend may be marketed under a memorable name, but that name does not establish its ingredients, quality or benefit. Ask for human evidence for the exact combination, not separate studies of different ingredients. More ingredients can also make adverse effects harder to attribute.
Is off-label use the same as an unapproved peptide?
Off-label use means an approved drug is used differently from its approved labeling, such as for another indication. FDA has not evaluated that unapproved use. An unapproved preparation or research chemical is a separate issue; calling it off-label does not make it an approved product.
Sources: [45] FDA
Are NAD+, B12 and collagen supplements all the same thing?
No. These are different products with different roles and evidence. A clinic's “peptide” menu may contain products from several categories. Ask for the precise active ingredient and product category rather than assuming every item has the same evidence or regulatory pathway.
Why consider an evaluation now?
Persistent symptoms, weight-related illness or concerns about bone health can deserve a timely diagnosis and appropriate treatment. There is no universal peptide deadline or evidence that you must buy an experimental injection now to preserve a healing window. Start by understanding the problem and comparing suitable options.
Sources: [74] NIH / NIDDK, [56] FDA-approved labeling
Why begin with RegenLuma?
Use this learning center to understand the options, examine original sources and prepare focused questions. Our developing brand emphasizes clear explanations, realistic goals and respectful decision-making. Confirm the treating clinician's qualifications, service availability, costs and follow-up arrangements before choosing care.
YOUR NEXT STEP
Start with your goals.
Leave with better questions.
An evaluation should explain the diagnosis, compare realistic options and identify an appropriate monitoring plan. A consultation does not guarantee a prescription.
Education only; clinical review pending. RegenLuma's clinicians, location and available services are still being confirmed. Do not send medical records through the general inquiry form.